UNION CITY, Calif.,
Nov. 23, 2015 /PRNewswire/
-- Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company
manufacturing point-of-care instruments and consumables for the
medical, research, and veterinary markets worldwide, announced
today the sale of 200 Piccolo Xpress® instruments to Fuzhou Kelian
Medical Devices Ltd ("Kelian"), a laboratory and point-of-care
diagnostics distributor based in Fuzhou,
China. Kelian will be placing the Piccolo units in neonatal
intensive care ("NICU") units, intensive care ("ICU") units, and
emergency room ("ER") departments in various provinces throughout
the People's Republic of China
("PRC").
Abaxis expects to deliver the 200 Piccolo units by the end of
the current quarter, which concludes on December 31, 2015.
Zhou Gong Ping, Managing Director
of Kelian, commented, "The Piccolo's ease-of-use, real time
results, and the small blood sample size required from patients
make it ideal for our hospital customers, especially in their NICU,
ICU and ER units. We look forward to working with Abaxis to better
serve our hospital and clinic customers for many years to
come."
Clint Severson, Chairman and
Chief Executive Officer of Abaxis, commented, "We are pleased to
have our Piccolo Xpress analyzers available to the medical
professionals of China. Our
point-of-care technology produces accurate and comprehensive test
results in minutes, improving patient diagnosis and treatment in a
most efficient manner. We are particularly pleased to be working
with an industry leader the caliber of Kelian to develop the
opportunity in the PRC."
Achim Henkel, Managing Director
of Abaxis Europe GmbH which is responsible for Abaxis' business in
China, commented, "The Piccolo
makes comprehensive, lab-quality chemistry results available to
healthcare practitioners in minutes—anytime, anywhere. We are
pleased to partner with Kelian to make this unique platform
available in what should be a key market for Abaxis moving
forward."
Piccolo Xpress
The Piccolo Xpress chemistry analyzer
for use in human patient care provides clinicians with rapid blood
constituent measurements. The Piccolo Xpress chemistry analyzer
provides on the spot routine multi-chemistry and electrolyte
results using a small patient sample size in any treatment setting.
The Piccolo Xpress chemistry analyzer can be operated with minimal
training and performs multiple routine general chemistry tests on
whole blood, serum or plasma samples. The system provides test
results in approximately 12 minutes with precision and accuracy
comparable to a clinical laboratory analyzer. The Piccolo Xpress
analyzer has a sophisticated Intelligent Quality Control (iQC)
system and proprietary algorithms that assure quality and
dependable results.
The Piccolo® menu features 31 blood chemistry tests that range
from liver, kidney and metabolic functions to lipids, electrolytes
and other specialty analytes. These 31 tests are conveniently
configured into 16 completely self-contained single use reagent
discs, 11 of which are CLIA waived. "CLIA waived" means the U.S.
Food and Drug Administration ("FDA") has categorized the test as
having waived status with respect to the Clinical Laboratory
Improvement Amendments of 1988 ("CLIA").
About Fuzhou Kelian Medical Devices
Fuzhou Kelian
Medical Devices Ltd, located in Fuzhou Cangshan Jinshan industrial
park, is a leading research, development and marketing company
specializing in in-vitro diagnostic ("IVD") reagents and point of
care diagnostic instruments. With a 20-year operating history,
Kelian has a national sales staff of 40 professionals throughout
the various provinces of the PRC and autonomous regions, and is
committed to continuous learning, improvement and innovation to
drive sales and operational performance.
About Abaxis
Abaxis, Inc. is a worldwide developer,
manufacturer and marketer of portable blood analysis systems that
are used in a broad range of medical specialties in human or
veterinary patient care to provide clinicians with rapid blood
constituent measurements. Our mission is to improve the
efficiency of care delivery to and the quality of life of patients
in the medical and veterinary markets. We provide leading
edge technology, tools and services that support best medical
practices, enabling physicians and veterinarians to respond to the
health needs of their clients at the point of care while operating
economical and profitable practices. For more information,
visit http://www.abaxis.com.
Forward Looking Statements
This press release
includes statements that constitute "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 (the "Reform Act"), including but not limited to statements
related to Abaxis' cash position, financial resources and potential
for future growth, market acceptance and penetration of new or
planned product offerings, and future recurring revenues and
results of operations. Abaxis claims the protection of the
safe-harbor for forward-looking statements contained in the Reform
Act. These forward-looking statements are often characterized
by the terms "may," "believes," "projects," "expects,"
"anticipates," or words of similar import, and do not reflect
historical facts. Specific forward-looking statements
contained in this press release or in Abaxis' conference call may
be affected by risks and uncertainties, including, but not limited
to, those related to risks related to the transition of its U.S.
medical sales to Abbott, potential excess inventory levels and
inventory imbalances at the company's distributors, losses or
system failures with respect to Abaxis' facilities or manufacturing
operations, the effect of exchange rate fluctuations on
international operations, fluctuations in quarterly operating
results, dependence on sole suppliers, the market acceptance of
Abaxis' products and services, the continuing development of its
products, required United States Food and Drug Administration
clearance and other government approvals, risks associated with
manufacturing and distributing its products on a commercial scale
free of defects, risks related to the introduction of new
instruments manufactured by third parties, risks associated with
competing in the human diagnostic market, risks related to the
protection of Abaxis' intellectual property or claims of
infringement of intellectual property asserted by third parties and
risks related to condition of the United
States economy. Readers should also refer to the
section entitled "Risk Factors" in Abaxis' annual report on Form
10‑K, and subsequently filed quarterly reports on Form 10‑Q filed
with the United States Securities and Exchange Commission.
Forward-looking statements speak only as of the date the statements
were made. Abaxis does not undertake and specifically
disclaims any obligation to update any forward-looking
statements.
Contact:
|
Clint
Severson
|
Lytham Partners,
LLC
|
|
Chief Executive
Officer
|
Joe Dorame, Joe Diaz
& Robert Blum
|
|
ABAXIS,
Inc.
|
602-889-9700
|
|
510-675-6500
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abaxis-inc-to-place-200-piccolo-xpress-instruments-in-the-peoples-republic-of-china-300183002.html
SOURCE Abaxis, Inc.